Biomaterial Database

[Oral actovegin therapy in cerebrovascular insufficiency. Studies on the therapeutic value of actovegin forte dragees in elderly patients with advanced cerebrovascular insufficiency]. 1979

H Kopp

The therapeutic effect of Actovegin forte drag. was investigated in a combined uncontrolled-controlled study on a total of 70 senile patients with mainly considerably advanced cerebral sclerosis (32 patients post-apoplexy) and concomitant diseases (46 patients with heart diseases, 41 patients with hypertonia, 28 patients with diabetes mellitus and others). Evaluation was made according to specific criteria. During six weeks of treatment with Actovegin a statistically significant and clinically relevant improvement of the intellectual faculties, the general condition and the complaints characterized by symptoms of deficiency of memory, exhaustiveness, disorder of sleep and weakness was noted. Even higher doses of the preparation were tolerated well. The effect of Actovegin forte drag. was dose-dependent--the best results were obtained with two dragées three times daily--and was clearly delimited from the effect of a parallel cardiac or circulatory therapy or of any other basic therapy. These results reveal that the therapy with orally administered Actovegin appears to be an appropriate supplement to the parenteral therapy with Actovegin which has so far only been possible. It is particularly suitable for ambulatory and prolonged treatment of senile patients with cerebrovascular insufficiency.

UI	MeSH Term	Description	Entries
D007360	Intelligence	The ability to learn and to deal with new situations and to deal effectively with tasks involving abstractions.
D008297	Male		Males
D008568	Memory	Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.
D002561	Cerebrovascular Disorders	A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	Brain Vascular Disorders,Intracranial Vascular Disorders,Vascular Diseases, Intracranial,Cerebrovascular Diseases,Cerebrovascular Insufficiency,Cerebrovascular Occlusion,Brain Vascular Disorder,Cerebrovascular Disease,Cerebrovascular Disorder,Cerebrovascular Insufficiencies,Cerebrovascular Occlusions,Disease, Cerebrovascular,Diseases, Cerebrovascular,Insufficiencies, Cerebrovascular,Insufficiency, Cerebrovascular,Intracranial Vascular Disease,Intracranial Vascular Diseases,Intracranial Vascular Disorder,Occlusion, Cerebrovascular,Occlusions, Cerebrovascular,Vascular Disease, Intracranial,Vascular Disorder, Brain,Vascular Disorder, Intracranial,Vascular Disorders, Brain,Vascular Disorders, Intracranial
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361	Drug Tolerance	Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL.	Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260	Female		Females
D006418	Heme	The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.	Ferroprotoporphyrin,Protoheme,Haem,Heme b,Protoheme IX
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man